155 related articles for article (PubMed ID: 10906417)
1. Genotoxicity of several clinically used topoisomerase II inhibitors.
Boos G; Stopper H
Toxicol Lett; 2000 Jul; 116(1-2):7-16. PubMed ID: 10906417
[TBL] [Abstract][Full Text] [Related]
2. Micronuclei in neonatal lymphocytes treated with the topoisomerase II inhibitors amsacrine and etoposide.
Slavotinek A; Perry PE; Sumner AT
Mutat Res; 1993 Nov; 319(3):215-22. PubMed ID: 7694143
[TBL] [Abstract][Full Text] [Related]
3. Formation of micronuclei and inhibition of topoisomerase II in the comet assay in mammalian cells with altered DNA methylation.
Stopper H; Eckert I; Wagener P; Schulz WA
Recent Results Cancer Res; 1997; 143():183-93. PubMed ID: 8912419
[No Abstract] [Full Text] [Related]
4. Are topoisomerase II inhibitor-induced micronuclei in vitro a predictive marker for the compounds' ability to cause secondary leukemias after treatment?
Stopper H; Boos G; Clark M; Gieseler F
Toxicol Lett; 1999 Jan; 104(1-2):103-10. PubMed ID: 10048755
[TBL] [Abstract][Full Text] [Related]
5. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
Holm B; Jensen PB; Sehested M
Cancer Chemother Pharmacol; 1996; 38(3):203-9. PubMed ID: 8646793
[TBL] [Abstract][Full Text] [Related]
6. Genotoxic activity of four inhibitors of DNA topoisomerases in larval cells of Drosophila melanogaster as measured in the wing spot assay.
Torres C; Creus A; Marcos R
Mutat Res; 1998 Mar; 413(2):191-203. PubMed ID: 9639703
[TBL] [Abstract][Full Text] [Related]
7. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II.
Bridewell DJ; Finlay GJ; Baguley BC
Cancer Chemother Pharmacol; 1999; 43(4):302-8. PubMed ID: 10071981
[TBL] [Abstract][Full Text] [Related]
9. The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.
Lanza A; Tornaletti S; Stefanini M; Evans HH; Ricanati M; Astaldi Ricotti GC; Pedrini AM
Carcinogenesis; 1993 Sep; 14(9):1759-63. PubMed ID: 8403196
[TBL] [Abstract][Full Text] [Related]
10. Genotoxicity of 17 gyrase- and four mammalian topoisomerase II-poisons in prokaryotic and eukaryotic test systems.
Albertini S; Chételat AA; Miller B; Muster W; Pujadas E; Strobel R; Gocke E
Mutagenesis; 1995 Jul; 10(4):343-51. PubMed ID: 7476271
[TBL] [Abstract][Full Text] [Related]
11. DNA strand breaks induced by the anti-topoisomerase II bis-dioxopiperazine ICRF-193.
Hajji N; Pastor N; Mateos S; Domínguez I; Cortés F
Mutat Res; 2003 Sep; 530(1-2):35-46. PubMed ID: 14563529
[TBL] [Abstract][Full Text] [Related]
12. Genotoxicity of inhibitors of DNA topoisomerases I (camptothecin) and II (m-AMSA) in vivo and in vitro.
Backer LC; Allen JW; Harrington-Brock K; Campbell JA; DeMarini DM; Doerr CL; Howard DR; Kligerman AD; Moore MM
Mutagenesis; 1990 Nov; 5(6):541-7. PubMed ID: 2175833
[TBL] [Abstract][Full Text] [Related]
13. Investigations into the biological relevance of in vitro clastogenic and aneugenic activity.
Parry JM; Fowler P; Quick E; Parry EM
Cytogenet Genome Res; 2004; 104(1-4):283-8. PubMed ID: 15162052
[TBL] [Abstract][Full Text] [Related]
14. Free radical scavengers can differentially modulate the genotoxicity of amsacrine in normal and cancer cells.
Blasiak J; Gloc E; Drzewoski J; Wozniak K; Zadrozny M; Skórski T; Pertynski T
Mutat Res; 2003 Feb; 535(1):25-34. PubMed ID: 12547280
[TBL] [Abstract][Full Text] [Related]
15. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines.
Fry AM; Chresta CM; Davies SM; Walker MC; Harris AL; Hartley JA; Masters JR; Hickson ID
Cancer Res; 1991 Dec; 51(24):6592-5. PubMed ID: 1660343
[TBL] [Abstract][Full Text] [Related]
16. Relationship between topoisomerase II levels and resistance to topoisomerase II inhibitors in lung cancer cell lines.
Houlbrook S; Harris AL; Carmichael J; Stratford IJ
Anticancer Res; 1996; 16(4A):1603-10. PubMed ID: 8712677
[TBL] [Abstract][Full Text] [Related]
17. International Commission for Protection Against Environmental Mutagens and Carcinogens. Mutagenicity and carcinogenicity of topoisomerase-interactive agents.
Anderson RD; Berger NA
Mutat Res; 1994 Aug; 309(1):109-42. PubMed ID: 7519727
[TBL] [Abstract][Full Text] [Related]
18. Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes.
Osheroff N; Corbett AH; Elsea SH; Westergaard M
Cancer Chemother Pharmacol; 1994; 34 Suppl():S19-25. PubMed ID: 8070023
[TBL] [Abstract][Full Text] [Related]
19. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
Rene B; Fosse P; Khelifa T; Jacquemin-Sablon A; Bailly C
Mol Pharmacol; 1996 Feb; 49(2):343-50. PubMed ID: 8632768
[TBL] [Abstract][Full Text] [Related]
20. Assays to predict the genotoxicity of the chromosomal mutagen etoposide -- focussing on the best assay.
Turner SD; Wijnhoven SW; Tinwell H; Lashford LS; Rafferty JA; Ashby J; Vrieling H; Fairbairn LJ
Mutat Res; 2001 Jun; 493(1-2):139-47. PubMed ID: 11516723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
